WO2000065077A8 - Triple hybrid amplicon vector systems to generate retroviral packaging lines - Google Patents
Triple hybrid amplicon vector systems to generate retroviral packaging linesInfo
- Publication number
- WO2000065077A8 WO2000065077A8 PCT/US2000/010669 US0010669W WO0065077A8 WO 2000065077 A8 WO2000065077 A8 WO 2000065077A8 US 0010669 W US0010669 W US 0010669W WO 0065077 A8 WO0065077 A8 WO 0065077A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- retrovirus
- vector
- cells
- hsv
- hybrid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13051—Methods of production or purification of viral material
- C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU43647/00A AU4364700A (en) | 1999-04-22 | 2000-04-21 | Triple hybrid amplicon vector systems to generate retroviral packaging lines |
EP00923545A EP1179083A4 (en) | 1999-04-22 | 2000-04-21 | Triple hybrid amplicon vector systems to generate retroviral packaging lines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13055199P | 1999-04-22 | 1999-04-22 | |
US60/130,551 | 1999-04-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000065077A1 WO2000065077A1 (en) | 2000-11-02 |
WO2000065077A8 true WO2000065077A8 (en) | 2001-10-11 |
Family
ID=22445216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/010669 WO2000065077A1 (en) | 1999-04-22 | 2000-04-21 | Triple hybrid amplicon vector systems to generate retroviral packaging lines |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1179083A4 (en) |
AU (1) | AU4364700A (en) |
WO (1) | WO2000065077A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3380605A1 (en) | 2015-11-24 | 2018-10-03 | GlaxoSmithKline Intellectual Property Development Limited | Transient transfection method for retroviral production |
RU2752498C2 (en) * | 2015-11-24 | 2021-07-28 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Stable cell lines for retroviruses production |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830725A (en) * | 1995-04-28 | 1998-11-03 | The Board Of Trustees For The Leland Stanford Junior University | Rapid, stable high-titre production of recombing retrovirus |
US5830727A (en) * | 1995-11-18 | 1998-11-03 | Human Gene Therapy Research Institute | Herpes simplex virus amplicon mini-vector gene transfer system |
EP0946733A4 (en) * | 1996-11-12 | 2003-01-08 | Gen Hospital Corp | Hsv/aav hybrid amplicon vectors |
-
2000
- 2000-04-21 AU AU43647/00A patent/AU4364700A/en not_active Abandoned
- 2000-04-21 EP EP00923545A patent/EP1179083A4/en not_active Withdrawn
- 2000-04-21 WO PCT/US2000/010669 patent/WO2000065077A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1179083A1 (en) | 2002-02-13 |
EP1179083A4 (en) | 2003-04-23 |
WO2000065077A1 (en) | 2000-11-02 |
AU4364700A (en) | 2000-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schaal et al. | Requirement of N-terminal amino acid residues of gp41 for human immunodeficiency virus type 1-mediated cell fusion | |
Wilkie et al. | Hybrid plasmids containing an active thymidine kinase gene of Herpes simplex virus 1 | |
Kanda et al. | Highly efficient CRISPR/Cas9-mediated cloning and functional characterization of gastric cancer-derived Epstein-Barr virus strains | |
Accotto et al. | Mapping of Digitaria streak virus transcripts reveals different RNA species from the same transcription unit. | |
NZ500740A (en) | Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV) | |
AU8067698A (en) | Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus | |
WO1997007225A3 (en) | High efficiency retroviral packaging system | |
WO2000034497A3 (en) | Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors | |
AU6871398A (en) | Method for enhancing expression of a foreign or endogenous gene product in pla nts | |
US7981676B2 (en) | Method for transfer of molecular substances with prokaryotic nucleic acid-binding proteins | |
Corbeau et al. | Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system | |
Hirai et al. | Use of EBV-based vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms | |
WO2004067710A3 (en) | Compositions and methods for tissue specific targeting of lentivirus vectors | |
WO2003093417A3 (en) | Lentiviral vector particles resistant to complement inactivation | |
PL324289A1 (en) | Encapsulated cells producing virus particles | |
CN101302537B (en) | Site-specific integration retroviral vector system and preparation thereof | |
WO2000065077A8 (en) | Triple hybrid amplicon vector systems to generate retroviral packaging lines | |
EP0816487A4 (en) | Recombinant human immunodeficiency virus-producing cell | |
AU1391295A (en) | Ribozymes targeting the retroviral packaging sequence expression construct s and recombinant retroviruses containing such constructs | |
AU5318496A (en) | Adenovirus vectors for gene therapy | |
Spannaus et al. | The prototype foamy virus protease is active independently of the integrase domain | |
WO2001044458A3 (en) | Bovine immunodeficiency virus (biv) based vectors | |
Zhang et al. | Targeted deletion of glycoprotein B gene by CRISPR/Cas9 nuclease inhibits gallid herpesvirus type 3 in dually infected Marek’s disease virus-transformed lymphoblastoid cell line MSB-1 | |
Okada et al. | In situ generation of pseudotyped retroviral progeny by adenovirus‐mediated transduction of tumor cells enhances the killing effect of HSV‐tk suicide gene therapy in vitro and in vivo | |
CA2331440A1 (en) | Amphotropic retrovirus packaging cell line, process for its production and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: PAT. BUL. 44/2000 UNDER (22) REPLACE "14.04.2000" BY "21.04.2000" |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000923545 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000923545 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000923545 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP |